## 5 Supplementary Materials:  
The following supporting information can be downloaded at: [[https://www.mdpi.com/article/10.3390/cancers16183219/s1](https://www.mdpi.com/article/10.3390/cancers16183219/s1)]([https://www.mdpi.com/article/10.3390/cancers16183219/s1](https://www.mdpi.com/article/10.3390/cancers16183219/s1)), FigureS1: Construction of SNU719_AR(-), SNU719_MICA(-), and SNU719_HLA-A(-) cells (A,B) SNU719_AR(-) cells were generated using the CRISPR/Cas9 system. _AR_ transcript and AR protein expression in SNU719_AR(-) cells were analyzed by RT-qPCR (A) and western blotting (B). (C,D) SNU719_MICA(-) cells were generated using the shRNA lentiviral system. _MICA_ transcript and MICA protein expression in SNU719_MICA(-) cells were analyzed by RT-qPCR (C) and western blotting (D). (E,F) SNU719_HLA-A(-) cells were generated using the shRNA lentiviral system. _HLA-A_ transcript and HLA-A protein expression in SNU719_HLA-A(-) cells were analyzed by RT-qPCR (E) and western blotting (F); Figure S2: p65 enrichment for RAFT1G upregulation. ChIP-seq analysis was conducted to identify p65 enrichment sites in the genome of SNU719 cells treated with 100 nM DHT for 30 min. The analysis focused on the enrichment of the p65 protein at the _RAETIG_ promoter locus, located at q23.2 of chromosome 6; Figure S3: Identification of HLA-A type in EBVaGC cells. (A) Comparison of _HLA-A_ exon 2 sequences. The _HLA-A_ 24:02 exon 2 sequence was obtained from NCBI GenBank (accession number: LT883521.1). DNA regions corresponding to _HLA-A_ exon 2 from EBVaGC cells and PBMCs were amplified and  
Figure 7: **Schematic illustrating the molecular mechanism by which DHT increases the cellular response of cellular immunity. ** DHT enters the cell, binds to the AR, and upregulates NF-kB through signaling. This upregulated NF-kB is phosphorylated in the cytoplasm and enters the nucleus where it acts as a transcriptional activator. This transcriptional activator promotes the transcription of _AR_, _MICA_ and _EBNA1_. The resulting AR is continuously bound to DHT to maintain signal transduction. The resulting MICA translocates to the cell membrane and acts as a ligand for the activating receptor NKG2D on NK cells and CD8* T cells. The resulting EBNA1 is then used as an antigenic peptide for MHC-1, which reacts with the main receptor (TCR) of CD8* T cells. analyzed using Sanger sequencing. Sequence alignment of exon 2 was performed using the MultAlin interface (multalin.toulouse.inra.fr/multalin/) accessed on 1 October 2023. (B) Comparison of _HLA-A_ exon 4 sequences. The _HLA-A_ 24:02 exon 4 sequence was obtained from NCBI GenBank (accession number: LT883521.1) accessed on 1 September 2023. DNA regions corresponding to _HLA-A_ exon 4 from EBVaGC cells and PBMCs were amplified and analyzed using Sanger sequencing. Sequence alignment of exon 4 was performed using the MultAlin interface (multalin.toulouse.inra.fr/multalin/) accessed on 1 October 2023; Figure S4: DHT-mediated p65 enrichment on the EBV genome. A ChIP-seq assay was conducted to identify genomic loci in the EBV genome of SNU719 cells treated with 100 nM DHT for 30 min, which resulted in p65 enrichment. (A) p65 protein enrichment on the _EBNA2_ exon at 36,402-36,490 bp of the EBV genome. (B) p65 protein enrichment on the _EBNA2_ exon at 37,254-37,281 bp of the EBV genome. (C) p65 protein enrichment on the _BRTR3_ exon at 49,654-49,673 bp of the EBV genome. (D) p65 protein enrichment on the _BLPF1_ exon at 54,549-54,814 bp of the EBV genome. (E) p65 protein enrichment on the _BDLF1_ promoter at 60,482-60,500 bp of the EBV genome. (F) p65 protein enrichment on the _BSLF2_ exon at 71,705-71,732 bp of the EBV genome. (G) p65 protein enrichment on the _B2 LF1_ exon at 90,481-90,506 bp of the EBV genome. (H) p65 protein enrichment on the _BBRF2_ 3'UTR at 95,795-95,945 bp of the EBV genome. (I) p65 protein enrichment on the _BALT2_ exon at 162,605-162,622 bp of the EBV genome. Conceptualization, H.K. and H.C.; methodology, D.S. ; software, I.J. and S.Y. ; validation, M.C., H.B. and S.H.L.